Cubist says faster treatment OK’d
LEXINGTON — Cubist Pharmaceuticals Inc. said yesterday that regulators gave a new approval to its antibiotic Cubicin, allowing Cubist to market a two-minute-injection version of the drug.
The company said the Food and Drug Administration approved the marketing of once-daily, two-minute IV injections of Cubicin, which treats complex skin infections like staph and the drug-resistant MRSA “superbug.’’
Cubist was originally approved in 2003 as a 30-minute infusion.
“Having to spend only 2 minutes a day receiving Cubicin, especially for patients in the outpatient setting, minimizes the impact that IV therapy has on their daily activities,’’ Cubist’s chief executive, Michael W. Bonney, said in a statement.
Cubist shares fell 73 cents, or 3.4 percent, to close at $20.98 yesterday.